🔥 Review: "Screening in Multiple Myeloma and Its Precursors: Are We There Yet?" by Sæmundur Rögnvaldsson, MD, PhD Sigrun Thorsteinsdottir Sigurdur Kristinsson University of Iceland. #MedX #MedTwitter #LabMedX #PathX #PathTwitter #Oncology 👇 buff.ly/3vvlM7h

woMMan of #Myeloma Nina Shah Irene Ghobrial marivi mateos Gurbakhash Kaur Surbhi Sidana, MD Noopur Raje Krina Patel Yi Lin Paula Rodriguez-Otero Eloisa Cartaxo VaniaHungria Ayk and many more. #mmsm #IMFIMWG #IMWG2024 #woMMan

One stop myelomarisk.com website update!! -Risk stratification calculators for Myeloma, SMM, MGUS, Waldenstrom, and Amyloidosis -Frailty calculator -mSMART Link for treatment -When to do bone marrow in MGUS NEW: Diagnosis of Light chain MGUS eatoure.github.io

🚀 Insights from #EHA2024! Dr Sigrun Thorsteinsdottir shared findings from the iSTOPMM study, proposing a new definition for LC-SMM and exploring MGUS in Iceland. Discover the latest in early detection and treatment.

📣 #ESHMM2024 STARTS ON OCTOBER 4th! Register now and join us in the South of France ➡ bit.ly/3WOpbaI 7th Translational Research Conference MULTIPLE #MYELOMA 🗓️ Oct. 4-6, 2024 in Mandelieu 🇫🇷 Chairs: Hartmut Goldschmidt, Martin Kaiser, Suzanne Lentzsch, MD, PhD #ESHCONFERENCES #MMsm

Screening for MGUS leads to earlier MM detection and significantly less CRAB symptoms at diagnosis. Use the iStopMM.com online risk model tool. #ESHMM2024 #ESHCONFERENCES #MMsm

Important iStopMM data on MGUS screening by Sigrun Thorsteinsdottir at #ESHMM2024 showing ⬆️ progression to SMM but not MM in the intervention arms! However, time to MM diagnosis and CRAB presentation slightly ⬇️ in the intervention arm! 🎯 Will this translate into a longer OS? 🎯what

Bruno Paiva presents important correlative data from QUIREDEX SMM trial (Rd vs Observation) showing that patients with MGUS-like phenotype don’t derive any benefit from intervention! What proportion of contemporary SMM patients (after excluding SLiM-CRAB and advanced

We're off to an amazing start of ESH (Haematology) #ESHMM2024 with Dr Dhodhapkar speaking in an excellent session on MGUS with Bruno Paiva and Dr Thorsteinsdottir from iStopMM , with excellent discussions on the progress in precursor statesof #MMsm

#ESHMM2024 great presentation and discussion by Sigrun Thorsteinsdottir 👉🏻iStopMM 👉🏻in SMM WB-MRI is very sensitive and identifies pt with lesions as active MM very early👉🏻WB-MRI will change our current assumption of progression rate of SMM to active MM due to earlier detection

Interesting data #mmsm Malin Hultcrantz MD PhD Theresia Akhlaghi Evaluating serum free light chain ratio as a biomarker in multiple myeloma N=466 Median FU: 5.5 yr In FLCr>=100 (n=65 pts): ✅TTP is 2.7 yr ✅2 yr progression can be as low as 17% (<2g M &<20% PC)👇 ➡️ haematologica.org/article/view/h…

#ESHMM2024 Thank you Hartmut Goldschmidt Martin Kaiser & Suzanne Lentzsch, MD, PhD & all our faculty for these great 3 days! Thanks also to all participants for engaging so actively with comments & questions! See you next year in Vienna for the 5th How to Diagnose and Treat #MMsm! #ESHCONFERENCES

Last week, my PhD student Ingigerður Sólveig defended her thesis at University of Iceland, titled "Looking Beyond the Lab: Risk Factors, Survival, and Comorbidity among Individuals with Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance." A proud moment! 🎓✨

📢 Our team, led by Christian Brieghel, introduces the Real-World International Staging System (RW-ISS) — a new tool to enhance risk stratification for newly diagnosed MM patients in Blood Cancer Journal: 🧬 doi.org/10.1038/s41408… 🧮 Try RW-ISS online: rwiss.shinyapps.io/RWISS/ #RWISS #MMSM

Proud to share our new paper validating revised FLC intervals for MGUS risk stratification. 🔬 32% reclassified to normal FLC ratio—no increased progression risk. ✅ Improved prognostic accuracy and more focused care for individuals with MGUS. #MMSM #iStopMM #MGUS

🧵1/ Our paper is out! A new study from the iStopMM team in JAMA Oncology shows how revising free light chain (FLC) reference intervals can reduce false positives for light chain MGUS (LC-MGUS). Let’s break it down 👇 jamanetwork.com/journals/jamao…

New paper in British Journal of Haematology 🧬📄→ doi.org/10.1111/bjh.70… We explore age-related differences in cytogenetic abnormalities in NDMM—and how these impact OS. 5 years in the making with great Nordic colleagues🤝✨ #MMSM #NMSG Annette Juul Vangsted Sæmundur Rögnvaldsson, MD, PhD Fredrik Schjesvold Tobias S. Slørdahl Emil Hermansen

Nice interview with Cecilie Mæng (Cecilie Velsø Mæng) about our recently published study that validates the #iStopMM revised FLC reference intervals, improving prognostic accuracy in MGUS ✨ ashpublications.org/ashclinicalnew…

#Myeloma Paper of the Day: iStopMM shows smoldering MM pts had more infxns (HR 1.36, 95% CI 1.07-1.73), antibacterial Rxs (1.24, 1.01-1.52) vs. comparators; SMM vs. MGUS had more infxns (1.37, 1.00-1.87); immunoparesis contributes to association: pubmed.ncbi.nlm.nih.gov/40940581/. #mmsm

Myeloma Paper of the Day, September 13th, Suggested by Robert Orlowski (Robert Z. Orlowski) Sigrun Thorsteinsdottir oncodaily.com/science/myelom… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews #MM #Myeloma #iStopMM CancerWorld